Advertisement.

NBSE Projected Dividend Yield

NeuBase Therapeutics Inc ( NASDAQ : NBSE )

NeuBase Therapeutics is a preclinical-stage biopharmaceutical company. Co. is developing a modular peptide-nucleic acid antisense oligo (PATrOL™) platform to address genetic diseases, with a single approach. Co.'s disclosed programs are: NT-0100 program, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the Huntington's disease deoxyribonucleic acid or ribonucleic acid (RNA); NT-0200, which is a PATrOL™-enabled therapeutic program being developed to target the mutant expansion in the dystrophy type 1 disease RNA; and NT-0300, which is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene.

20 YEAR PERFORMANCE RESULTS

NBSE Dividend History Detail
NBSE Dividend News
NBSE Competitors News

# of Shares: 0

Closing Price: 0.38

Current Market Value: 0.00

Cost Basis: 0.00

Date Acquired:

Dividend Cash Flow
Year	Annual Dividend	Dividend Growth	# of Shares	Annual Dividend Income	Yield On Cost %
2014	0.00	0%	0	$ 0.00	0.00%
2015	0.00	0%	0	$ 0.00	0.00%
2016	0.00	0%	0	$ 0.00	0.00%
2017	0.00	0%	0	$ 0.00	0.00%
2018	0.00	0%	0	$ 0.00	0.00%
2019	0.00	0%	0	$ 0.00	0.00%
2020	0.00	0%	0	$ 0.00	0.00%
2021	0.00	0%	0	$ 0.00	0.00%
2022	0.00	0%	0	$ 0.00	0.00%
2023	0.00	0%	0	$ 0.00	0.00%
2024	0.00	0%	0	$ 0.00	0.00%
2025	0.00	0%	0	$ 0.00	0.00%
Using the current years Dividend Growth rate of 0% and projecting 0% forward the annual dividend income in 10/yrs would be $ 0.00 with a yield on cost % of 0.00%
Rolling Last 4 qtrs dividends total $ 0.00 and Previous last 4 qtrs dividends total $ 0.00
Dividend 1 Yr Growth = ( 0.00 – 0.00 ) × 100 = 0% (Click the Edit pencil if you want to modify the forward dividend growth rate projection) 0.00

Year	Declaration Date	Ex-Dividend Date	Record Date	Payable Date	Dividend $ Amount
Total:					0.0000